Drug intelligence / Profile preview

Zestra

Development stage: Phase 3
Lead developer: Aytu BioPharma
Administration: Topical

Overview

Zestra is a topically applied botanical oil blend designed to enhance sexual arousal, desire, and satisfaction in women. Developed by Qualilife Pharmaceuticals (and later marketed by Innovus Pharmaceuticals and Aytu BioPharma), it is composed of a proprietary mixture of botanical ingredients including borage seed oil, evening primrose oil, angelica root extract, and coleus forskohlii extract. The product is intended to increase local sensitivity and blood flow to the clitoral area through a localized mechanism of action. It has been evaluated in clinical trials for female sexual dysfunction (FSD), specifically mixed desire, arousal, and orgasm disorders.

Brand names: ZestraZestra Essential Arousal Oil
Other names: Zestra

Targets

AC (Adenylyl cyclase family)

Beyond the preview

Go deeper on Zestra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zestra.

Explore the full profile